S. R. Patel, V. Gandhi, J. Jenkins, et al., “Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation,” Journal of Clinical Oncology, Vol. 19, No. 15, 2001, pp. 3483-3489.

has been cited by the following article:

• TITLE: Advanced Breast Angiosarcoma Completely Responding to Chemotherapy

  AUTHORS: Zhiguo Luo, Qian Wang, Wei Peng, Jianhua Chang, Xichun Hu, Xiaonan Hong

  KEYWORDS: Angiosarcoma; Lung Metastases; Gemcitabine; Chemotherapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.4, May 31, 2013

  ABSTRACT: Introduction: For patients with anthracycline-resistant metastatic angiosarcoma, currently there is no available standard for second-line therapy and there is a need for novel effective regimens to improve response rates. Case report: We reported here about a case of a primary angiosarcoma of both breasts in a 34-year-old woman presenting lung metastases. At the completion of 3 cycles of the MAID regimen including mesna, adriamycin, ifosfamide and dacarbazine, CT showed progression of the disease (PD). Subsequently second-line chemotherapy was started using GVP regimen consisting of gemcitabine, vincristine and cisplatin. Complete response (CR) of the lung metastases was achieved after 6 treatment cycles. Conclusion: In the absence of an effective therapy among patients with anthracycline-resistant metastatic breast angiosarcoma, a GVP chemo-regimen can be performed as a selective option.